Attenta™
Active ingredients: Methylphenidate
Consumer medicine information
For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).
What this medicine is used for
Attention deficit hyperactivity disorder (ADHD). ADHD was previously known as attention deficit disorder. Other terms being used to describe this behavioural syndrome include minimal brain dysfunction in children, hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction, and psycho-organic syndrome of children. Attenta is indicated as part of a comprehensive treatment program which typically includes other remedial measures (psychological, educational, social) for achieving a beneficial effect in children with a behavioural syndrome characterised by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity (not always present) and impulsivity. The diagnosis of this syndrome should not be made when these symptoms are only of recent origin. Non-localising (soft) neurological signs, emotional lability, learning disability and an abnormal electroencephalogram (EEG) may or may not be present, and a diagnosis of CNS dysfunction may or may not be warranted. Special diagnostic considerations for ADHD. The aetiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but also of psychological, educational and social resources. Characteristics commonly reported include chronic history or short attention span, distractibility, emotional lability, impulsivity, moderate to severe hyperactivity, minor neurological signs and an abnormal EEG. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics. Drug treatment is not indicated for all children with this syndrome. Stimulants are not intended for use in children who exhibit symptoms secondary to environmental factors (eg. child abuse in particular) or primary psychiatric disorders. Appropriate educational placement is essential and psychosocial intervention is generally necessary. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the doctor's assessment of the chronicity and severity of the child's symptoms. Narcolepsy. The symptoms include daytime sleepiness, inappropriate sleep episodes and rapidly occurring loss of voluntary muscle tone. Effective for symptoms of sleepiness but not for loss of voluntary muscle tone.
Source: ARTG
Storage conditions
- Shelf lifetime is 18 Months
- Store below 25 degrees Celsius
Source: ARTG
How to use this medicine
Non-composite pack
This medicine contains one component only.
Component
- Tablet, uncoated
- Oral
- 7mm white flat bevel edged tablet, debossed with "MP" and "10" either side of a central breakline on one side, and "Greek Alpha Symbol" on the reverse.
Source: ARTG
Do I need a prescription?
These medicines require authorisation for prescription from your doctor. It is Schedule 8: Controlled Drug.
- 100 tablets
Source: ARTG
Is this medicine subsidised?
This medicine is not listed on the Pharmaceutical Benefits Scheme (PBS). Talk to your pharmacist about how much it will cost.
Source: PBS
Pregnant or planning a pregnancy?
For the active ingredient: Methylphenidate
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Source: AHT
Reporting side effects
If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).
You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)
Source: ARTG
Data sources
- Australian Health Thesaurus (AHT) (Opens in new tab) – Last updated on 1 October 2026
- Australian Medicines Terminology (AMT) (Opens in new tab) – Last updated on 1 October 2026
- Australian Register of Therapeutic Goods (ARTG) (Opens in new tab) – Last updated on 1 October 2026
- Pharmaceutical Benefits Scheme (PBS) (Opens in new tab) – Last updated on 1 October 2026
- Medicines Information Pty Ltd (Opens in new tab) – Last updated on 4 March 2026
Disclaimer
Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).
Symptom Checker
Worried about your health?
Select a symptom, answer some questions, get advice
